Literature DB >> 15390241

Treatment of slow/no-reflow phenomenon with intracoronary nitroprusside injection in primary coronary intervention for acute myocardial infarction.

Huang-Joe Wang1, Ping-Hang Lo, Jen-Jyh Lin, Han Lee, Jui-Sung Hung.   

Abstract

Slow/no-reflow phenomenon is a serious problem complicating primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) and is associated with a poor prognosis. From January 2002 to November 2002, 11 of the 70 consecutive patients with ST elevation AMI who were subjected to primary PCI using balloon angioplasty and/or stenting developed slow/no-reflow phenomenon (TIMI 1 flow in 2, TIMI 2 in 8, and TIMI 2.5 in 1). They were 10 men and 1 woman, aged 64 +/- 11 years (range, 46-81). The culprit vessels were six in the left anterior descending coronary artery, three in the right coronary artery, one in the left circumflex coronary artery, and one in saphenous vein graft. Multiple bolus doses (100 microg) of nitroprusside were injected into the index artery through the guiding catheter using a 3 ml syringe until the TIMI flow grade improved by at least one grade or the systolic pressure decline below 80 mm Hg (one patient). The total drug dose varied from 100 to 700 microg. Following the drug treatment, angiographic TIMI flow grade improved by at least one grade in 9 (82%) of the 11 patients (P = 0.007). The TIMI frame counts significantly decreased from 36 +/- 17 frame counts to 16 +/- 11 frame counts (P = 0.012). All patients were discharged without major adverse cardiovascular events. Intracoronary bolus injection of nitroprusside using a 3 ml syringe appears to be a feasible, safe, and effective technique for the management of slow/no-reflow phenomenon complicating primary PCI. (c) 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15390241     DOI: 10.1002/ccd.20149

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  14 in total

Review 1.  Pathogenesis of myocardial ischemia-reperfusion injury and rationale for therapy.

Authors:  Aslan T Turer; Joseph A Hill
Journal:  Am J Cardiol       Date:  2010-08-01       Impact factor: 2.778

Review 2.  Intracoronary pharmacotherapy in the management of coronary microvascular dysfunction.

Authors:  Vijayalakshmi Kunadian; Cafer Zorkun; Scott P Williams; Leah H Biller; Alexandra M Palmer; Katherine J Ogando; Michelle E Lew; Navin Nethala; William J Gibson; Susan J Marble; Jacqueline L Buros; C Michael Gibson
Journal:  J Thromb Thrombolysis       Date:  2008-09-26       Impact factor: 2.300

3.  Long-term prognostic impact of the attenuated plaque in patients with acute coronary syndrome.

Authors:  Hiroyuki Okura; Toru Kataoka; Minoru Yoshiyama; Junichi Yoshikawa; Kiyoshi Yoshida
Journal:  Heart Vessels       Date:  2014-09-03       Impact factor: 2.037

4.  The use of intracoronary sodium nitroprusside to treat no-reflow after primary percutaneous coronary intervention in acute myocardial infarction.

Authors:  Milorad B Tesic; Goran Stankovic; Vladan Vukcevic; Miodrag C Ostojic
Journal:  Herz       Date:  2010-04-08       Impact factor: 1.443

5.  Comparison of the effects of nitroprusside versus nicorandil on the slow/no-reflow phenomenon during coronary interventions for acute myocardial infarction.

Authors:  Renpei Kobatake; Tetsuya Sato; Yasukazu Fujiwara; Haruki Sunami; Ryo Yoshioka; Tetsuya Ikeda; Hironori Saito; Toru Ujihira
Journal:  Heart Vessels       Date:  2010-11-26       Impact factor: 2.037

6.  Pathophysiology, Diagnosis, and Management of Coronary No-Reflow Phenomenon.

Authors:  Gagan Kaur; Patrick Baghdasaryan; Balaji Natarajan; Prabhdeep Sethi; Ashis Mukherjee; Padmini Varadarajan; Ramdas G Pai
Journal:  Int J Angiol       Date:  2022-01-13

Review 7.  Drosophila melanogaster innate immunity: an emerging role for peptidoglycan recognition proteins in bacteria detection.

Authors:  J Royet
Journal:  Cell Mol Life Sci       Date:  2004-03       Impact factor: 9.261

Review 8.  Pathophysiology, Diagnosis, and Management of Coronary No-Reflow Phenomenon.

Authors:  Gagan Kaur; Patrick Baghdasaryan; Balaji Natarajan; Prabhdeep Sethi; Ashis Mukherjee; Padmini Varadarajan; Ramdas G Pai
Journal:  Int J Angiol       Date:  2021-03-03

9.  The REFLO-STEMI trial comparing intracoronary adenosine, sodium nitroprusside and standard therapy for the attenuation of infarct size and microvascular obstruction during primary percutaneous coronary intervention: study protocol for a randomised controlled trial.

Authors:  Sheraz A Nazir; Jamal N Khan; Islam Z Mahmoud; John P Greenwood; Daniel J Blackman; Vijay Kunadian; Martin Been; Keith R Abrams; Robert Wilcox; A A Jennifer Adgey; Gerry P McCann; Anthony H Gershlick
Journal:  Trials       Date:  2014-09-25       Impact factor: 2.279

Review 10.  Treating and preventing no reflow in the cardiac catheterization laboratory.

Authors:  Ryan Berg; Cyrus Buhari
Journal:  Curr Cardiol Rev       Date:  2012-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.